Neil L. Berkley

ProLung, Inc. is a medical technology company, which specializes in predictive analytics technology, early stage lung cancer risk testing. It develops, tests and commercializes solutions which are designed to accelerate the time to diagnosis and expand the therapeutic window for lung cancer patients. Its product under the name of ProLung Test was developed to assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography scan. The company was founded by Steven C. Eror on November 19, 2004 and is headquartered in Salt Lake City, UT.

MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA.

Vaxiion Therapeutics, Inc. operates as a biotechnology company. Its nanodelivery platforms are based on genetically engineered, non-living bacterial minicells that are capable of packaging, targeting and delivering a wide array of therapeutically relevant molecules (including protein toxins, small molecule drugs, RNAi, plasmids, peptides and imaging agents) directly to cancer cells. The company was founded by Roger Allen Sabbadini, Neil L. Berkley and William Gerhart in 2000 and is headquartered in San Diego, CA.

Navigen, Inc. operates as a drug discovery and development company. The company was founded by Hunter Jackson and is headquartered in Salt Lake City, UT.